RecruitingPhase 2NCT04981509
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Studying Hereditary clear cell renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ramaprasad Srinivasan, M.DNational Cancer Institute LAO
- Intervention
- Atezolizumab(biological)
- Enrollment
- 65 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2027
Study locations (13)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Emory University Hospital Midtown, Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- NCI - Center for Cancer Research, Bethesda, Maryland, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- NYU Langone Hospital - Long Island, Mineola, New York, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04981509 on ClinicalTrials.gov